For patients who have not responded to antidepressants, the American Psychiatric Association (APA) now recommends TMS therapy as a second-line treatment.
Transcranial magnetic stimulation (TMS) is a non-invasive technique that applies brief magnetic pulses to the brain in order to activate neurons in the relevant brain structure to release neurotransmitters that affect mood. Patients treated with standard TMS experienced an average reduction in their depression symptom score of 22.1%.1
However, standard TMS coils are limited to the activation of cortical brain regions, up to a depth of approximately 1.5 cm. While many patients have found relief with this technology, our Brainsway Deep TMS can penetrate into much deeper areas of the brain directly rather than through propagation. This represents a true breakthrough, capable of inducing excitation or inhibition of neurons deep inside the brain’s limbic system structure, which impact mood regulation and motivation.
TMS Center of Colorado was the first facility to offer TMS therapy in Colorado, and the first to offer Brainsway Deep TMS. The Brainsway Deep TMS System is FDA cleared in the U.S. for the treatment of depressive episodes in adult patients suffering from depression who have failed to achieve improvement from antidepressant medication. Clinical studies are underway for a number of additional disorders, including bipolar disorder, PTSD, chronic pain, OCD, adult AD/HD and other addictions. The FDA does not clear these additional indications at this point.
If you are a healthcare professional and would like more information or wish to consult with us about a specific patient, please contact Dr. Ted Wirecki at (303) 502-9430
It is estimated that 20-40% of patients do not benefit adequately from pharmacotherapy and psychotherapy
“Growing support from controlled trials, systematic reviews, meta-analyses, naturalistic outcome studies, and professional guidelines indicate that TMS has an increasingly important role in clinical practice.”
1. Philip G. Janicak, MD et al, Current Psychiatry June 2016; 15(6):49-56